Matrix Metalloproteinases and their Inhibitors - Friend or Foe

Tumor Microenvironment

Volumn , Issue , 2010, Pages 53-76

  Rojiani, Mumtaz V ^a   Wiranowska, Marzenna ^a   Rojiani, Amyn M ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Invasive and metastatic activities of cancer cells contributing morbidity and mortality; Mammalian family of matrix metalloproteinases; Matrilysins, MMP 7 and MMP 26 roles in degradation and processing of ECM and non ECM proteins; Matrix metalloproteinases and their inhibitors friend or foe; MMP impact on tumor microenvironment and growth; Modulating change within physiologic and tumor microenvironment matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs); Pleiotropic nature of MMPs diversity of functions in cancer progression; Targets and substrates of MMP action cellular or extracellular; Tissue inhibitors of matrix metalloproteinases; Tumor associated fibroblasts role in cancer progression and angiogenesis

Indexed keywords

EID: 84863674581     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470669891.ch4     Document Type: Chapter

References (135)

1. Albini, A., Melchiori, A., Santi, L. et al. (1991) Tumor cell invasion inhibited by TIMP-2. Journal of National Cancer Institute, 83, 775-779.
2. Alexander, C.M., Howard, E.W., Bissell, M.J., and Werb, Z. (1996) Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. Journal of Cell Biology, 135, 1669-1677.
3. Alvarez, O.A., Carmichael, D.F., and Declerck, Y.A. (1990) Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. Journal of National Cancer Institute, 82, 589-595.
4. Amour, A., Slocombe, P.M., Webster, A. et al. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Letters, 435, 39-44.
5. Anand-Apte, B., Pepper, M.S., Voest, E. et al. (1997) Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Investigative Ophthalmology and Visual Science, 38, 817-823.
6. Andarawewa, K.L., Boulay, A., Masson, R. et al. (2003) Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Research, 63, 5844-5849.
7. Ardi, V.C., Van Den Steen, P.E., Opdenakker, G. et al. (2009) Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. The Journal of Biological Chemistry, 284, 25854-25866.
8. Baeriswyl, V. and Christofori, G. (2009) The angiogenic switch in carcinogenesis. Seminars in Cancer Biology, 19, 329-337.
9. Baker, A.H., George, S.J., Zaltsman, A.B. et al. (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. British Journal of Cancer, 79, 1347-1355.
10. Belotti, D., Paganoni, P., Manenti, L. et al. (2003) Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Research, 63, 5224-5229.
11. Bendardaf, R., Buhmeida, A., Hilska, M. et al. (2010) MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Investigation, 28, 38-43.
12. Bergers, G., Brekken, R., Mcmahon, G. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2, 737-744.
13. Bertaux, B., Hornebeck, W., Eisen, A.Z., and Dubertret, L. (1991) Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. Journal of Investigative Dermatology, 97, 679-685.
14. Bloomston, M., Shafii, A., Zervos, E.E. et al. (2002) MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer. Journal of Surgical Research, 102, 35-38.
15. Boudreau, N., Werb, Z., and Bissell, M.J. (1996) Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proceedings of the National Academy of Sciences of the United States of America, 93, 3509-3513.
16. Brand, K., Baker, A.H., Perez-Canto, A. et al. (2000) Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Research, 60, 5723-5730.
17. Brew, K., Dinakarpandian, D., and Nagase, H. (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta, 1477, 267-283.
18. Celiker, M.Y., Wang, M., Atsidaftos, E. et al. (2001) Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene, 20, 4337-4343.
19. Chesler, L., Golde, D.W., Bersch, N., and Johnson, M.D. (1995) Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood, 86, 4506-4515.
20. Corcoran, M.L. and Stetler-Stevenson, W.G. (1995) Tissue inhibitor of metalloproteinase- 2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. The Journal of Biological Chemistry, 270, 13453-13459.
21. Cornelius, L.A., Nehring, L.C., Harding, E. et al. (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. Journal of Immunology, 161, 6845-6852.
22. Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295, 2387-2392.
23. Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481-490.
24. Crocker, S.J., Pagenstecher, A., and Campbell, I.L. (2004) The TIMPs tango with MMPs and more in the central nervous system. Journal of Neuroscience Research, 75, 1-11.
25. Davidson, B., Goldberg, I., Kopolovic, J. et al. (1999) MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecologic Oncology, 73, 372-382.
26. Davis, G.E. and Senger, D.R. (2008) Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression. Current Opinion in Hematology, 15, 197-203.
27. Dean, R.A. and Overall, C.M. (2007) Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Molecular and Cellular Proteomics, 6, 611-623.
28. DeMers, N., Rojiani, A.M., Brem, S., and Rojiani, M.V. (eds) (2010) Molecular Mechanisms of Metastasis to the CNS, in press.
29. Deryugina, E.I. and Quigley, J.P. (2006) Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews, 25, 9-34.
30. Deryugina, E.I. and Quigley, J.P. (2010) Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochimica et Biophysica Acta, 1803 (1), 103-20.
31. Deryugina, E.I., Soroceanu, L., and Strongin, A.Y. (2002) Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Research, 62, 580-588.
32. Docherty, A.J., Lyons, A., Smith, B.J. et al. (1985) Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature, 318, 66-69.
33. Egeblad, M. and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2, 161-174.
34. Fang, J., Shing, Y., Wiederschain, D. et al. (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proceedings of the National Academy of Sciences of the United States of America, 97, 3884-3889.
35. Fanjul-Fernandez, M., Folgueras, A.R., Cabrera, S., and Lopez-Otin, C. (2010) Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta, 1803 (1), 3-19.
36. Fernandez, H.A., Kallenbach, K., Seghezzi, G. et al. (1999) Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. Journal of Surgical Research, 82, 156-162.
37. Fingleton, B. (2008) MMP inhibitor clinical trials-the past, present, and future, in The Cancer Degradome (eds D. Edwards, G. Hoyer-Hansen, F. Blasi and B.F. Sloane), Springer, New York, pp. 759-785.
38. Folkman, J. (2004) Endogenous angiogenesis inhibitors. APMIS, 112, 496-507.
39. Fong, K.M., Kida, Y., Zimmerman, P.V., and Smith, P.J. (1996) TIMP1 and adverse prognosis in non-small cell lung cancer. Clinical Cancer Research, 2, 1369-1372.
40. Frisch, S.M. and Francis, H. (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. Journal of Cell Biology, 124, 619-626.
41. Gao, G., Plaas, A., Thompson, V.P. et al. (2004) ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. The Journal of Biological Chemistry, 279, 10042-10051.
42. Garg, P., Sarma, D., Jeppsson, S. et al. (2010) Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Research, 70, 792-801.
43. Genis, L., Galvez, B.G., Gonzalo, P., and Arroyo, A.G. (2006) MT1-MMP: universal or particular player in angiogenesis? Cancer and Metastasis Reviews, 25, 77-86.
44. Gorrin-Rivas, M.J., Arii, S., Furutani, M. et al. (2000) Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clinical Cancer Research, 6, 1647-1654.
45. Gross, J. and Lapiere, C.M. (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proceedings of the National Academy of Sciences of the United States of America, 48, 1014-1022.
46. Guedez, L., Courtemanch, L., and Stetler-Stevenson, M. (1998a) Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood, 92, 1342-1349.
47. Guedez, L., Stetler-Stevenson, W.G., Wolff, L. et al. (1998b) In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. Journal of Clinical Investigation, 102, 2002-2010.
48. Guedez, L.,Mcmarlin, A.J., Kingma, D.W. et al. (2001) Tissue inhibitor of metalloproteinase- 1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. American Journal of Pathology, 158, 1207-1215.
49. Gutierrez-Fernandez, A., Fueyo, A., Folgueras, A.R. et al. (2008) Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Research, 68, 2755-2763.
50. Ha, H.Y., Moon, H.B., Nam, M.S. et al. (2001) Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Research, 61, 984-990.
51. Hayakawa, T., Yamashita, K., Ohuchi, E., and Shinagawa, A. (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). Journal of Cell Science, 107 (Pt 9), 2373-2379.
52. Hewitt, R.E., Brown, K.E., Corcoran, M., and Stetler-Stevenson, W.G. (2000) Increased expression of tissue inhibitor ofmetalloproteinases type 1 (TIMP-1) in amore tumourigenic colon cancer cell line. Journal of Pathology, 192, 455-459.
53. Hobson, J.P., Liu, S., Rono, B. et al. (2006) Imaging specific cell-surface proteolytic activity in single living cells. Nature Methods, 3, 259-261.
54. Iozzo, R.V. and San Antonio, J.D. (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. Journal of Clinical Investigation, 108, 349-355.
55. Itoh, Y. and Seiki,M. (2006) MT1-MMP: a potent modifier of pericellular microenvironment. Journal of Cellular Physiology, 206, 1-8.
56. Jiang, Y., Wang, M., Celiker, M.Y. et al. (2001) Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Research, 61, 2365-2370.
57. Jones, J.L., Glynn, P., and Walker, R.A. (1999) Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. Journal of Pathology, 189, 161-168.
58. Joo, Y.E., Seo, K.S., Kim, H.S. et al. (2000) Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Digestive Diseases and Science, 45, 114-121.
59. Jost, M., Folgueras, A.R., Frerart, F. et al. (2006) Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Research, 66, 5234-5241.
60. Jung, K.K., Liu, X.W., Chirco, R. et al. (2006) Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO Journal, 25, 3934-3942.
61. Kalluri, R. (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nature Reviews Cancer, 3, 422-433.
62. Kerkela, E., Ala-Aho, R., Klemi, P. et al. (2002) Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. Journal of Pathology, 198, 258-269.
63. Khokha, R. (1994) Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. Journal of the National Cancer Institute, 86, 299-304.
64. Khokha, R., Waterhouse, P., Yagel, S. et al. (1989) Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science, 243, 947-950.
65. Kossakowska, A.E., Urbanski, S.J., and Edwards, D.R. (1991) Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non- Hodgkin's lymphomas. Blood, 77, 2475-2481.
66. Kruger, A. (2009) Functional genetic mouse models: promising tools for investigation of the proteolytic internet. Biological Chemistry, 390, 91-97.
67. Lambert, E., Bridoux, L., Devy, J. et al. (2009) TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival. International Journal of Biochemistry and Cell Biology, 41, 1102-1115.
68. Lambert, E., Dass'e, E., Haye, B., and Petitfrere, E. (2004) TIMPs as multifacial proteins. Critical Reviews in Oncology/Hematology, 49, 187-198.
69. Lee, S., Jilani, S.M., Nikolova, G.V. et al. (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. Journal of Cell Biology, 169, 681-691.
70. Leppert, D., Lindberg, R.L., Kappos, L., and Leib, S.L. (2001) Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Research: Brain Research Reviews, 36, 249-257.
71. Lewis, C.E. and Pollard, J.W. (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66, 605-612.
72. Li, G., Fridman, R., and Kim, H.R. (1999) Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Research, 59, 6267-6275.
73. Liu, X.W., Bernardo, M.M., Fridman, R., and Kim, H.R. (2003) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. The Journal of Biological Chemistry, 278, 40364-40372.
74. Liu, X.W., Taube, M.E., Jung, K.K. et al. (2005) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Research, 65, 898-906.
75. Lopez-Otin, C. and Matrisian, L.M. (2007) Emerging roles of proteases in tumour suppression. Nature Reviews Cancer, 7, 800-808.
76. Lukashev, M.E. and Werb, Z. (1998) ECM signalling: orchestrating cell behaviour and misbehaviour. Trends in Cell Biology, 8, 437-441.
77. Malemud, C.J. (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Frontiers in Bioscience, 11, 1696-1701.
78. Martin, M.D. and Matrisian, L.M. (2007) The other side of MMPs: protective roles in tumor progression. Cancer and Metastasis Reviews, 26, 717-724.
79. Matsuzawa, K., Fukuyama, K., Hubbard, S.L. et al. (1996) Transfection of an invasive human astrocytoma cell line with a TIMP-1 cDNA: modulation of astrocytoma invasive potential. Journal of Neuropathology and Experimental Neurology, 55, 88-96.
80. Mccarthy, K., Maguire, T., Mcgreal, G. et al. (1999) High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. International Journal of Cancer, 84, 44-48.
81. Michael, M., Babic, B., Khokha, R. et al. (1999) Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. Journal of Clinical Oncology, 17, 1802-1808.
82. Murate, T., Yamashita, K., Ohashi, H. et al. (1993) Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity. Experimental Hematology, 21, 169-176.
83. Murphy, A.N., Unsworth, E.J., and Stetler-Stevenson, W.G. (1993) Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. Journal of Cellular Physiology, 157, 351-358.
84. Murphy, G., Houbrechts, A., Cockett, M.I. et al. (1991) The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry, 30, 8097-8102.
85. Nemeth, J.A. and Goolsby, C.L. (1993) TIMP-2, a growth-stimulatory protein from SV40- transformed human fibroblasts. Experimental Cell Research, 207, 376-382.
86. Nii, M., Kayada, Y., Yoshiga, K. et al. (2000) Suppression of metastasis by tissue inhibitor of metalloproteinase-1 in a newly established human oral squamous cell carcinoma cell line. International Journal of Oncology, 16, 119-124.
87. Niskanen, E., Gasson, J.C., Teates, C.D., and Golde, D.W. (1988) In vivo effect of human erythroid-potentiating activity on hematopoiesis in mice. Blood, 72, 806-810.
88. Nyberg, P., Xie, L., and Kalluri, R. (2005) Endogenous inhibitors of angiogenesis. Cancer Research, 65, 3967-3979.
89. O'Reilly, M.S., Holmgren, L., Shing, Y. et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328.
90. Oh, J., Takahashi, R., Kondo, S. et al. (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell, 107, 789-800.
91. Packard, B.Z., Artym, V.V., Komoriya, A., and Yamada, K.M. (2009) Direct visualization of protease activity on cells migrating in three-dimensions. Matrix Biology, 28, 3-10.
92. Paez-Ribes, M., Allen, E., Hudock, J. et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15, 220-231.
93. Page-Mccaw, A., Ewald, A.J., and Werb, Z. (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews: Molecular and Cellular Biology, 8, 221-233.
94. Patterson, B.C. and Sang, Q.A. (1997) Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). The Journal of Biological Chemistry, 272, 28823-28825.
95. Powe, D.G., Brough, J.L., Carter, G.I. et al. (1997) TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. British Journal of Cancer, 75, 1678-1683.
96. Pozzi, A., Moberg, P.E., Miles, L.A. et al. (2000) Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proceedings of the National Academy of Sciences of the United States of America, 97, 2202-2207.
97. Presta, M., Dell'era, P., Mitola, S. et al. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Reviews, 16, 159-178.
98. Qi, J.H., Ebrahem, Q., Moore, N. et al. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine, 9, 407-415.
99. Ritter, L.M., Garfield, S.H., and Thorgeirsson, U.P. (1999) Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochemical and Biophysical Research Communications, 257, 494-499.
100. Rodriguez, D., Morrison, C.J., and Overall, C.M. (2010) Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. Biochimica et Biophysica Acta, 1803 (1), 39-54.
101. Rojiani, A.M., Lin, J.T., Korabathina, K. et al. (2001) Expression of MMP-2 CorrelatesWith Increased Angiogenesis at CNS/Metastatic Carcinoma Interface. Journal of Neuropathology and Experimental Neurology, 60, 444.
102. Rojiani,M.V. and Rojiani, A.M. (2005) Aggressive growth pattern of H2009 lung carcinoma following TIMP-1 overexpression in CNS metastasis model. AACR Meeting Abstracts, Apr 2005, 38.
103. Rojiani, M.V. and Rojiani, A.M. (2006) Down-regulation of Thrombospondin-1 following TIMP-1 overexpression in lung carcinoma enhances angiogenesis. AACR Meeting Abstracts, Apr 2006, 655-656.
104. Rowe, T.F., King, L.A., Macdonald, P.C., and Casey, M.L. (1997) Tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 expression in human amnion mesenchymal and epithelial cells. American Journal ofObstetrics and Gynecology, 176, 915-921.
105. Sabeh, F., Shimizu-Hirota, R., andWeiss, S.J. (2009) Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. Journal of Cell Biology, 185, 11-19.
106. Sanderson, R.D., Yang, Y., Kelly, T. et al. (2005) Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. Journal of Cellular Biochemistry, 96, 897-905.
107. Schultz, R.M., Silberman, S., Persky, B. et al. (1988) Inhibition by human recombinant tissue inhibitor ofmetalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Research, 48, 5539-5545.
108. Seiki, M. (2002) The cell surface: the stage for matrix metalloproteinase regulation of migration. Current Opinion in Cell Biology, 14, 624-632.
109. Seo, D.W., Li, H., Guedez, L. et al. (2003) TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell, 114, 171-180.
110. Sloane, B.F., Sameni, M., Podgorski, I. et al. (2006) Functional imaging of tumor proteolysis. Annual Review of Pharmacology and Toxicology, 46, 301-315.
111. Sternlicht, M.D., Lochter, A., Sympson, C.J. et al. (1999) The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell, 98, 137-146.
112. Stetler-Stevenson, W.G., Bersch, N., and Golde, D.W. (1992) Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Letters, 296, 231-234.
113. Still, K., Robson, C.N., Autzen, P. et al. (2000) Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate, 42, 18-25.
114. Stockmann, C., Doedens, A., Weidemann, A. et al. (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature, 456, 814-818.
115. Valente, P., Fassina, G., Melchiori, A. et al. (1998) TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. International Journal of Cancer, 75, 246-253.
116. Van Beem, R.T., Verloop, R.E., Kleijer, M. et al. (2009) Blood outgrowth endothelial cells from cord blood and peripheral blood: angiogenesis-related characteristics in vitro. Journal of Thrombosis and Haemostasis, 7, 217-226.
117. Van Hinsbergh, V.W. and Koolwijk, P. (2008) Endothelial sprouting and angiogenesis:matrix metalloproteinases in the lead. Cardiovascular Research, 78, 203-212.
118. Visscher, D.W., Hoyhtya, M., Ottosen, S.K. et al. (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. International Journal of Cancer, 59, 339-344.
119. Wang, M., Liu, Y.E., Greene, J. et al. (1997) Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene, 14, 2767-2774.
120. Watanabe,M., Takahashi, Y., Ohta, T. et al. (1996) Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer, 77, 1676-1680.
121. Wen, W., Moses, M.A., Wiederschain, D. et al. (1999) The generation of endostatin is mediated by elastase. Cancer Research, 59, 6052-6056.
122. Williamson, R.A.,Marston, F.A., Angal, S. et al. (1990) Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochemical Journal, 268, 267-274.
123. Wiranowska, M. and Naidu, A.K. (1994) Interferon effect on glycosaminoglycans in mouse glioma in vitro. Journal of Neurooncology, 18, 9-17.
124. Wiranowska, M., Plaas, A. (2008) Cytokines and extracellular matrix remodeling in the central nervous system, in NeuroImmune Biology (eds C. Phelps and E.A. Korneva), Elsevier, Edinburgh, pp. 167-197.
125. Wiranowska, M., Tresser, N., and Saporta, S. (1998) The effect of interferon and anti-CD44 antibody on mouse glioma invasiveness in vitro. Anticancer Research, 18, 3331-3338.
126. Wiranowska, M., Rojiani, A.M., Gottschall, P., Moscinski, L., Johnson, J., and Saporta, S. (2000). CD44 expression and MMP-2 secretion by mouse glioma cells: effect of interferon and anti-CD44 antibody. Anticancer Research, 20, 4301-4306.
127. Wiranowska, M., Ladd, S., Smith, S.R., and Gottschall, P.E. (2006) CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain Cell Biology, 35, 159-172.
128. Wolf, K.,Mazo, I., Leung, H. et al. (2003) Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. Journal of Cell Biology, 160, 267-277.
129. Wolf, K., Wu, Y.I., Liu, Y. et al. (2007) Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nature Cell Biology, 9, 893-904.
130. Yamada, E., Tobe, T., Yamada, H. et al. (2001) TIMP-1 promotes VEGF-induced neovascularization in the retina. Histology and Histopathology, 16, 87-97.
131. Yang, T.T. and Hawkes, S.P. (1992) Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 89, 10676-10680.
132. Yoshiji, H., Gomez, D.E., and Thorgeirsson, U.P. (1996) Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. International Journal of Cancer, 69, 131-134.
133. Yoshiji, H., Harris, S.R., Raso, E. et al. (1998) Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. International Journal of Cancer, 75, 81-87.
134. Yu, Q. and Stamenkovic, I. (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Development, 13, 35-48.
135. Zeng, Z.S., Cohen, A.M., Zhang, Z.F. et al. (1995) Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clinical Cancer Research, 1, 899-906.